Cannabis Law Report

FEBRUARY 28, 2022

Bronner’s, Partners with Pioneering Health Plan Administrator, Enthea, to Provide Psychedelic Therapy as Employee Healthcare Benefit. Leading US Company to Offer Employee Coverage for Ketamine Assisted Therapy to Promote Mental Health. First Ever Partnership Between Health Plan Administrator and.

Therapy 52

Therapy Treatment Research and Development Advocacy 52

Cannabis Law Report

JULY 22, 2021

A master distribution agreement has been signed with My Green Planet, a leading global agricultural supply group, giving Sporeo access to approximately 7,000 retailers across North America, Australia, and Europe. Levitee Labs aims to catalyze access to compounds and alternative medicines that enhances the wellbeing of society.

eCommerce 105

eCommerce Therapy Media Access 105

Cannabis Law Report

DECEMBER 11, 2021

The UK’s first and highest-rated medical cannabis clinic, Sapphire Medical Clinics , has today announced that it is reducing the cost of its consultations and appointments for patients enrolled through the Sapphire Access Scheme. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

Cannabis Law Report

DECEMBER 8, 2021

Access to headline, upfront, milestone and royalty data. Access to hundreds of Psychiatry deal contract documents. Comprehensive access to over 780 Psychiatry deal records. Specific therapy indication. Access Psychiatry deal headline, upfront, milestone and royalty data. Advanced Cooling Therapy.

Access 40

Access Data Pharmaceutical Research and Development 40

The Cannigma

AUGUST 5, 2022

2 In 2019 the FDA approved a keta m ine-based nasal spray to treat depression that does not respond to other therapies. Most existing research does not support the use of THC in combating depression and there is very limited data for other cannabinoids.” Depression and psychedelics. Who could you be if you felt better?

Treatment 141

Treatment Research and Development Therapy Digestion 141

Veriheal

OCTOBER 20, 2021

Veriheal does not support illegally consuming alternative therapeutic substances but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting psychedelic therapy. A Magical Future.

Therapy 98

Therapy Microdosing Decriminalization Consumption 98

Veriheal

MAY 26, 2022

Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy. RoC also works to increase patients’ access to medical cannabis by helping U.S.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

The Joint Blog

NOVEMBER 4, 2019

The study found that 58% of physicians agree that “medical cannabis was a legitimate medical therapy.” ” However, as noted by NORML, around half of respondents “expressed discomfort in talking to their patients about medical cannabis options, a finding that is also consistent with prior data. A majority (>?50%)

Therapy 42

Therapy Clinical Trials Conditions Patients 42

Cannabis Law Report

JANUARY 6, 2022

This blog post will explain how psilocybin patenting and other factors could make Oregon’s psilocybin program prohibitively expensive for low-income patients, and how big pharma is maneuvering to monopolize psychedelic therapy. The FDA will likely refer to this data as it considers formal approval for psilocybin therapy and products.

Access 52

Access Patients Research and Development Treatment 52

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Promoting Research and Innovation The medical marijuana industry promotes research and innovation in the field of cannabis-based therapies.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. About RYAH Group, Inc.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

SEPTEMBER 28, 2021

The TGA has approved the use of MDMA and Psilocybin to treat mental illness in Australia by qualified medical professionals under a special access scheme. My ANIP host organisation (Johnathan Davis MLA’s office) may also use the data. If you withdraw no data from your response will be saved. Participant Information Sheet.

Therapy 52

Therapy Medicine Data Collective 52

Cannabis Law Report

AUGUST 2, 2021

The diversified venture fund is focused on tackling the growing global mental health crisis by investing in innovative psychedelic-based and adjacent therapies that are poised to shape the future of psychiatry and fields beyond. Innovative psychedelic-based and adjacent therapies are poised to shape the future of psychiatry and fields beyond.

Research and Development 98

Research and Development Therapy Collective Treatment 98

Cannabis Law Report

JULY 20, 2021

With our new psychedelic medicinal insurance solutions, business can access the necessary coverages to protect their business, attract qualified officers/directors, and bring new treatments to market.”. Rahn & Associates announced today that it launched new risk management solutions for the burgeoning psychedelic medicinal industry.

Medicine 75

Medicine Business Research and Development Chronic Pain 75

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Veriheal

JANUARY 4, 2021

Medicinal cannabinoid therapies are saving and changing lives for people across America and around the world. Individuals like Coltyn Turner, Alexis Bortell, and the late Charlotte Figi helped show America the power of cannabis and cannabinoid therapies, and thanks to the access we have to information today, their stories reached the masses.

Chronic Pain 105

Chronic Pain Therapy Cannabinoids Treatment 105

SpeedWeed

JULY 10, 2021

The law also expands the qualifying conditions for eligibility to include cancer remission therapy, as well as spinal cord or central nervous system damage with “indication of intractable spasticity and other associated neuropathies,” according to the bill’s text. In addition, H.B. That list will be updated annually. View original article.

Access 52

Access Research and Development Programs Chronic Pain 52

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S. Drug Enforcement Agency (DEA). Is the future exciting?

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Veriheal

JUNE 30, 2023

Researchers say this emphasizes just how important it is that psilocybin therapy be done in a controlled setting with therapy and community-based after-care. The 14-page document covers several aspects of the drug development process, including trial best practices, data collection, and new drug application requirements.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

TheAnswerPage

JANUARY 11, 2022

As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Who monitors their health and the long-term effects of the marijuana therapy?

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 23, 2021

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). PROGRAMME.and.ABSTRACTS. Patient-reported outcomes. Peer-reviewed analysis.

Cannabinoids 45

Cannabinoids Data Chronic Pain Sleep 45

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Additionally, there are misleading practices of “p-hacking” where researchers can manipulate data through different statistical tests (thanks to modern computer programs) looking for statistically significant findings.

Research and Development 121

Research and Development Data THC Clinical Trials 121

Canna Law Blog

APRIL 13, 2019

These products have not been shown to be safe or effective, and deceptive marketing of unproven treatments may keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”. Specifically, the agency fears that.

CBD 103

CBD Safety Topical Food 103

Cannabis Law Report

JUNE 29, 2021

Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant.

Clinical Trials 105

Clinical Trials Research and Development Data Patients 105

The Cannigma

FEBRUARY 2, 2021

Patients can also access CBD products without a prescription through local pharmacies. Our data confirm that PD patients have a high interest in treatment with medicinal cannabis but lacked knowledge about how to take it and especially the differences between the two main cannabinoids, THC and CBD,” said Buhmann.

Patients 97

Patients Clinical Trials Research and Development Treatment 97

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52

SpeedWeed

SEPTEMBER 17, 2021

million to assess the efficacy of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI). Wesana is a serious, thoughtful and ethical company engaged in the development of psychedelic-assisted therapy. Lately, MAPS research zeroed in on MDMA-assisted therapy for PTSD.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

OCTOBER 13, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. and his conclusion.

Research and Development 52

Research and Development Therapy Access Data 52

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. Accessed August 2021. Accessed March 2021.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. PRESS RELEASE. ” About COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

APRIL 12, 2019

I am also prescribed pharmacological and non-pharmacological therapies and try to keep a base of exercise and good nutrition. CFAMM’s goal is to support medical cannabis patients, improve their outcomes and enable them to obtain fair and safe access to their medication. million medical cannabis patients in Canada. About CFAMM.

Access 45

Access Patients Marijuana Medicine 45

Veriheal

DECEMBER 27, 2022

The subjective nature of self-reported data can plague research. Scientists Hope New Findings Will Help Expand Research on Psychedelic Therapy. Always consult a physician before attempting alternative therapies. To combat this, researchers of this new study quizzed participants in an actual, knowledge-based test.

Research and Development 102

Research and Development Therapy Consumption DEA 102

Cannabis Law Report

JULY 6, 2021

Johnson, DSc, MD, MPhil, FRCPsych said, “I am pleased to join the Ehave Medical Advisory Board and look forward to working towards bringing psychedelic-assisted therapies to patients experiencing substance use issues. Forward-Looking Statement Disclaimer.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

The Cannigma

SEPTEMBER 13, 2021

Also in 2020, Israel surpassed Germany as the world’s largest importer of medical cannabis flower, according to data from Israel’s online Cannabis Magazine. Can foreigners access medical marijuana? The Israeli website cannapedia also posted in 2021 a lengthy price list for legal medical cannabis flower and oil in Israel.

Legalization 111

Legalization Decriminalization Patients Cannabis 111

Cannabis Law Report

AUGUST 10, 2021

The deal also provides the group with the ability to build upon MTL’s current brand portfolio, and develop a diverse flower menu bringing premium, accessible products to cannabis consumers while maintaining existing supply agreements. Enhanced retail sales portfolio through immediate access to brands distributed in Québec; and.

Seed-To-Sale 105

Seed-To-Sale Cultivation Patients Cannabis 105

Cannabis Law Report

JUNE 17, 2021

Silo Wellness is a publicly traded company on the CSE with a consumer-facing platform for the sale of functional mushroom products, psilocybin mushroom production in Jamaica, and the facilitation of psychedelic wellness retreats in both Jamaica and Oregon that incorporate a variety of psychedelic-augmented therapies.

Research and Development 75

Research and Development Therapy Access Media 75

Cannabis Law Report

MARCH 9, 2022

“These amendments honour and build on those practices while allowing us to do novel clinical research and deepen the body of scientific data for scaled development and greater public access to much-needed therapies.” ” About Numinus.

Research and Development 52

Research and Development Therapy Access Medicine 52